|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Sorafenib in radioactiveiodine-refractory,locally advanced or metastatic differentiatedthyroid cancer: a randomised, double-blind, phase 3 trial 显示文摘 | Brose MS Nutting CM Jarzab B | 2014 | Lancet2014，384，9940： | 1 |
| 2 | Vemurafenib in patients with BRAFV6OOE-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non- randomised, muhicentre, open-label, phase 2 trial 显示文摘 | Brose MS Cabanillas ME Cohen EEW | 2016 | Lancet Oncol2016，111，： | 1 |
| 3 | Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program显示文摘 | Brose MS Rebbeck TR Calzone KA | | 0，，18： | 1 |
| 4 | Cancer risk esti- mates for BRCAI mutation carriers identified in a risk evalua- tion program显示文摘 | Brose MS Rebbeck TR Calzone KA | 2002 | J Natl Cancer Inst2002，94，： | 1 |
| 5 | Rationale and design of decision:a double-blind,randomized,placebo-controlled phase Ⅲtrial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory,differentiated thyroid cancer显示文摘 | Brose MS Nutting CM Sherman SI | | 0，，： | 1 |
| 6 | Nicholson ABRAF and RAS mutations in human lung cancer and melanoma显示文摘 | Brose MS Volpe P Feldman M | 2002 | Cancer Res2002，62，23： | 1 |
| 7 | BRAF and RAS mutations in human lung cancer and melanoma显示文摘 | Brose MS Volpe P Feldman M | | 0，，23： | 1 |
| 8 | BRAF and RAS mutation in human lung cancer and melanoma显示文摘 | Brose MS Volpe P Feldman M | 2002 | Cancer Res2002，62，12： | 1 |
| 9 | Rationale and design ofdecision : a double - blind,randomized, placebo - controlled phaseIII trial evaluating the efficacy and safety of sorafenib in patientswith locally advanced or metastatic radioactive iodine ( RAI) - re-fractory ,differentiated thyroid cancer 显示文摘 | Brose MS Nutting CM Sherman SI | 2011 | BMC Cancer2011，11，： | 1 |
| 10 | Effect of BRAF V600E onresponse to sorafenib in advanced thyroid cancer patients 显示文摘 | Brose MS Troxel AB Redlinger M | 2009 | ProcAm Soc Clin Oncol2009，27，15： | 1 |
| 11 | Sorafenib in radioac- tiveiodine-refractory, locally advanced or metastaticdifferentiated thyroid cancer: a randomised, double-blind, phase 3 trial显示文摘 | Brose MS Nutting CM Jarzab B | 2014 | Lancet2014，384，9940： | 1 |
| 12 | Sorafenib in radioactive i- odine-refractory, locally advanced or metastatic differentiated thy- roid cancer: a randomized, double-blind, phase 3 trial显示文摘 | Brose MS Nutting CM Jarzab B | 2014 | Lan- cet2014，384，7： | 1 |
| 13 | A Phase I Study of Cabozantinib (XLI84) in Patients with Differentiated Thyroid Cancer显示文摘 | Cabanillas ME Brose MS Holland J | 2014 | Thyroid2014，24，10： | 1 |
| 14 | BRAF and RAS mu- tations in human lung cancer and melanoma显示文摘 | Brose MS Volpe P Feldman M | 2002 | Cancer Res2002，62，23： | 1 |
| 15 | Management of sor- afenib-related adverse events : a clinician's perspective 显示文摘 | Brose MS Frenette CT Keefe SM et at | 2014 | Semin Oncol2014，41，2： | 1 |
| 16 | BRAF and RAS mutations in human lung cancer and melanoma显示文摘 | Brose MS Volpe P Feldman M | 2002 | Cancer Res2002，62，23： | 1 |
| 17 | Sorafenih in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial 显示文摘 | Brose MS Nutting CM Jarzab B | 2014 | Lancet2014，384，9940： | 1 |
| 18 | BRAF and RAS mutations in human lung cancer and melanoma显示文摘 | Brose MS Volpe P Feldman M | 2002 | Cancer Res2002，62，23： | 1 |
| 19 | In search of a real 'targeted' therapy for thyroid cancer显示文摘 | Brose MS | 2012 | Clin Cancer Res2012，18，7： | 1 |
| 20 | Sorafenib in radioactive iodine- refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial 显示文摘 | Brose MS Nutting CM Jarzab B | 2014 | Lancet2014，384，9940： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员